Myocardial Infarction
📧 Sign up to get email alerts when something new happens for Myocardial Infarction.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-18EMA Authorised: Arixtra (fondaparinux sodium) — Viatris Healthcare Limited
The EMA authorised Arixtra (fondaparinux sodium) for venous thrombosis, pulmonary embolism, myocardial infarction, and unstable angina, unde…
-
EMA approval · 2026-08-03EMA Authorised: Clopidogrel Zentiva (previously Clopidogrel Winthrop) (clopidogrel) — Zentiva k.s.
Authorisation granted for Clopidogrel Zentiva (clopidogrel), expanding or confirming its availability for stroke, peripheral vascular diseas…
-
EMA approval · 2026-07-21EMA Authorised: Metalyse (tenecteplase) — Boehringer Ingelheim International GmbH
EMA authorised Metalyse (tenecteplase) for treatment in myocardial infarction with Boehringer Ingelheim as the MAH.
-
EMA approval · 2026-06-11EMA Authorised: DuoPlavin (clopidogrel;acetylsalicylic acid) — Sanofi Winthrop Industrie
DuoPlavin, a fixed-dose combination of clopidogrel and acetylsalicylic acid, has been authorised by EMA for acute coronary syndrome and myoc…
-
FDA approval · 2026-02-06FDA Approved: TICAGRELOR — Original Application (Lifestar Pharma LLC)
The FDA approved Lifestar Pharma LLC's original ANDA for ticagrelor, a P2Y12 receptor inhibitor used to reduce thrombotic cardiovascular eve…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-02-05EMA Authorised: Clopidogrel Zentiva (previously Clopidogrel Winthrop) (clopidogrel) — Zentiva k.s.
The European Medicines Agency authorised Zentiva’s generic clopidogrel product for prevention of stroke, myocardial infarction, acute corona…
-
EMA approval · 2026-01-29EMA Authorised: Arixtra (fondaparinux sodium) — Viatris Healthcare Limited
The EMA authorised Arixtra (fondaparinux sodium) by Viatris Healthcare Limited for thromboembolic conditions including venous thrombosis, pu…
-
EMA approval · 2025-12-12EMA Authorised: Clopidogrel Viatris (previously Clopidogrel Taw Pharma) (clopidogrel besilate) — Viatris Limited
The EMA has authorized Clopidogrel Viatris (clopidogrel besilate) for use in preventing thrombotic events in patients with peripheral vascul…
-
EMA approval · 2025-11-27EMA Authorised: Metalyse (tenecteplase) — Boehringer Ingelheim International GmbH
The European Medicines Agency authorised Metalyse (tenecteplase) by Boehringer Ingelheim International GmbH for the treatment of myocardial …
-
EMA approval · 2025-11-13EMA Authorised: Efient (prasugrel) — Substipharm
The EMA has authorised Efient (prasugrel) by Substipharm for indications including acute coronary syndrome, unstable angina, and myocardial …
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (BIONPHARMA INC.)
FDA approved an original application for ticagrelor from Bionpharma Inc., making a generic version of this antiplatelet medication available…
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (Dr. Reddys Laboratories Inc)
FDA approved Dr. Reddy's Laboratories' original application for ticagrelor as a generic version of the antiplatelet drug, expanding access t…
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (Oryza Pharmaceuticals, Inc.)
FDA approved the ticagrelor product from Oryza Pharmaceuticals, Inc. under its original application (ANDA 208508).
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (Radha Pharmaceuticals INC)
FDA approves Radha Pharmaceuticals INC's original ANDA for Ticagrelor, a generic antiplatelet medication.
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved an Original Application for ticagrelor from Novadoz Pharmaceuticals LLC, indicating the approval of a generic ticagrelor produc…
-
EMA approval · 2025-09-26EMA Authorised: Prasugrel Viatris (previously Prasugrel Mylan) (prasugrel besilate) — Viatris Limited
EMA authorised Prasugrel Viatris (prasugrel besilate) by Viatris Limited; the product is approved for myocardial infarction, acute coronary …
-
FDA approval · 2025-08-28FDA Approved: LOPRESSOR — Original Application (VALIDUS PHARMACEUTICALS LLC)
FDA approved Lopressor (metoprolol tartrate) via the original application for METOPROLOL TARTRATE by Validus Pharmaceuticals LLC under NDA 2…
-
EMA approval · 2025-08-26EMA Authorised: Iscover (clopidogrel) — Sanofi Winthrop Industrie
The European Medicines Agency has authorised Iscover, a clopidogrel product from Sanofi Winthrop Industrie, for preventing thrombotic events…
-
FDA approval · 2025-08-01FDA Approved: CLOPIDOGREL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for clopidogrel from Amneal Pharmaceuticals LLC under the ANDA process (generic product).
-
FDA approval · 2025-07-30FDA Approved: ATENOLOL — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for Atenolol submitted by Rising Pharma Holdings, Inc.
-
EMA approval · 2025-07-14EMA Authorised: Plavix (clopidogrel hydrogen sulfate) — Sanofi Winthrop Industrie
The EMA authorised Plavix (clopidogrel hydrogen sulfate) for use with indications including stroke, peripheral vascular disease, atrial fibr…
-
EMA approval · 2025-06-23EMA Authorised: Grepid (clopidogrel (as besilate)) — Pharmathen S.A.
EMA authorised the drug Grepid, containing clopidogrel besilate, for indications including peripheral vascular diseases, stroke, and myocard…
-
FDA approval · 2025-06-11FDA Approved: METOPROLOL TARTRATE — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for metoprolol tartrate (Hospira, Inc.), a generic beta-blocker, confirming continued approval of th…
-
EMA approval · 2025-05-14EMA Authorised: Clopidogrel Krka (clopidogrel (as hydrochloride)) — Krka, d.d., Novo mesto
EMA authorised Clopidogrel Krka (clopidogrel hydrochloride) on 14 May 2025 for reducing cardiovascular events in patients with peripheral ar…
-
EMA approval · 2025-05-14EMA Authorised: Zyllt (clopidogrel (as hydrogen sulfate)) — Krka, d.d., Novo mesto
EMA authorised Zyllt, a clopidogrel hydrogen sulfate product by Krka, d.d., Novo mesto. It is indicated for preventing vascular events in pa…